Abstract
In 10 patients (8 men and 2 women) aged 28 to 58 years (mean 44.4 years) treated by repeated haemodialysis due to end-stage renal failure, the bleeding time, whole-blood coagulation time, one-stage prothrombin time, thrombin time of plasma, activated partial thromboplastin time (APTT), fibrinogen level and euglobulin lysis time have been determined (1) during a 4-hour haemodialysis using heparin as an antithrombotic agent, and (2) one week later in the course of another haemodialysis using prostacyclin-heparin. The values for any of the above parameters with both anticoagulant treatment types did not differ. Plasma fibrinogen level after haemodialysis was significantly lower after administration of heparin alone as compared with the group treated by prostacyclin-heparin infusion. During haemodialysis performed with prostacyclin-heparin infusion, activation of the blood fibrinolytic system was manifested by a significant shortening of euglobulin lysis time, observed after 1.5 hours and after the end of haemodialysis. The above phenomenon did not occur when haemodialysis was performed with heparin alone.
Similar content being viewed by others
References
Barrowclife, T. W., Johnson, E. A., Thomas, D.: Antithrombin III and heparin.Br. Med. Bull., 34, 143 (1978).
Caruana, R. J., Raja, R. M., Bush, J. K., Kramer, M. S., Goldstein, S. J.: Heparin free dialysis: Comparative data results in high risk patients.Kidney Int., 31, 1351 (1987).
Cheney, K., Bonnin, J. A.: Haemorrhage platelet dysfunction and other coagulation defects in uremia.Br. J. Haematol., 8, 215 (1962).
Dembińska-Kieć, A., Kostka-Trabka, E., Gryglewski, R. J.: Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans.Thromb. Haemostas. (Stuttgart),47, 190 (1982).
Di Minno, G., Martinez, J., McKean, M.: Platelet dysfunction in uremia: Multifaceted defect partially corrected by dialysis and normal fibrinogenBlood, 60, 198 (1982).
Glaser, P., Guesde, R., Rouby, J. J., Eurin, B.: Hemodialysis without heparin is possible.Lancet, 1, 579 (1979).
Gryglewski, R. J., Szczeklik, A., Niżankowski, R.: Anti-platelet action of intravenous prostacyclin in man.Thromb. Res., 15, 153 (1978).
Hassanein, A. A., McNicol, G.P., Douglas, A. S.: Relationships between platelet function tests in normal and uraemic subjects.J. Clin. Pathol., 23, 402 (1970).
Horowitz, H. I., Cohen, B. D., Martinez, P., Papayaanou, M. F.: Defective ADP-induced platelet factor-3 activation in uremia.Blood, 30, 331 (1967).
Jubelier, S. J.: Hemostatic abnormalities in renal disease.Am. J. Kidney Dis., 5, 219 (1985).
Lee, R. G., Adamson, C., Kim, S. W.: Competitive adsorption of plasma proteins onto polymer surfaces.Thromb. Res., 4, 485 (1974).
Lindsay, R. M., Prentice, C. R. M., Davidson, J. F., Burton, J. A., McNicol, G. P.: Haemostatic changes during dialysis associated with thrombus formation of dialysis membranes.Br. Med. J., 4, 454 (1972).
Livio, M., Gotti, E., Marchesi, D., Mecca, G., Remuzzi, G., De Gaetano, G.: Uraemic bleeding: Role of anaemia and beneficial effect of red cell transfusions.Lancet, 2, 1013 (1982).
Longmore, D. B., Gueirrara, D., Bennet, S., Smith, M., Bunting, S., Reed, P., Moncada, S., Read, N. G.: Prostacyclin: a solution to some problems of extracorporeal circulation.Lancet, 1, 1002 (1979).
Mannuci, P. M., Remuzzi, G., Pusineri, F., Lombardi, R., Valtecchi, C., Mecca, G., Zimmerman, T. S.: Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.N. Engl. J. Med., 308, 8 (1983).
Marshall, J. W., Ahearn, D. J., Nothum, R. J., Esterly, J., Nolph, K. D., Maher, J. F.: Adherence of blood components to dialyzer membranes — morphological studies.Nephron, 12, 157 (1974).
Meier, H. L., Scott, C. F., Mandle, R., Jr., Webster, M. E., Pierce,R. W., Colman, R. W., Kaplan, A. P.: Requirements for contact activation of human Hageman factorAnn. N. Y. Acad. Sci., 28, 93 (1977).
Nath, N., Lowery, C. T., Niewiarowski, S.: Antigenemic and antiheparin properties of human platelet factor IV (PF IV).Blood, 45, 535 (1975).
O'Grady, J., Warrington, S., Moti, M. J., Bunting, S., Flower, R., Fowle, A. S. E., Higgs, E. A., Moncada, S.: Effects of intravenous infusion of prostacyclin (PGI2) in man.Prostaglandins, 19, 319 (1980).
Ostrowski, W.: Wybrane metody z chemii klinicznej. PZWL, Warszawa 1968.
Parzer, S., Panzer, S., Balcke, P., Mannhalter, C.: Identification of proteins adsorbed from human blood hemodialysis membranes during standard hemodialysis. Abstr. XXV. Congr. EDTA, 1988, p. 188.
Rabiner, S. F.: Uremic bleeding.Prog. Hemost. Thromb., 1, 233 (1972).
Rabiner, S. F., Hrodeck, O.: Platelet factor-3 in normal subjects and patients with renal failure.J. Clin. Invest., 47, 901 (1968).
Remuzzi, G., Dodesini, P., Livio, M.: Parathyroid hormone inhibits human platelet function.Lancet, 2, 1321 (1981).
Remuzzi, G., Livio, M., Cavenaghi, A. E., Marchesi, D., Mecca, G., Donati, M. B., Gaetano, G.: Unbalanced prostaglandin synthesis and plasma factors in uremic bleeding. A hypothesis.Thromb. Res., 13, 531 (1978).
Remuzzi, G., Marchesi, D., Cavenaghi, A. E.: Bleeding in renal failure: a possible role of vascular prostacyclin (PGI2).Clin. Nephrol., 12, 127 (1979).
Rosenberg, R. D.: Actions and interactions of antithrombin and heparin.N. Engl.J. Med., 292, 146 (1975).
Rosenberg, R. D.: Heparin action.Circulation, 49, 603 (1974).
Rudowski, W.: Zaburzenia hemostazy w chirurgii. PZWL, Warszawa 1971.
Rylance, P. B., Dodd, N. J., Gordge, M. P., Ireland, H., Lane, D., Weston, M. J.: Prostacyclin (Epoprostenol) allows reduced heparin dosage during haemodialysis. Abstr. XX. Congr. EDTA, 1983, p. 113.
Salzman, W., Rosenberg, R. D., Smith, M. H., Lindon, J. N., Favreau, L.: Effect of heparin and heparin fractions on platelet aggregation.Am. Soc. Clin. Invest., 65, 64 (1980).
Smith, M., Danviriyasup, K., Crow, J., Cato, A., Park, G., Hassid, A., Dunn, M.: Prostacyclin substitution for heparin in long-term hemodialysis.Am. J. Med., 73, 669 (1982).
Stockenhuber, F., Kyrle, P. A., Sunder-Plabmann, G., Blacke, P., Lechner, K.: Bleeding tendency in chronic renal failure: evidence for an increased generation of prostacyclin in the microvasculature and platelet storage pool defect. Abstr. XXV. Congr. EDTA, 1988, p. 196.
Turney, J. H., Fewell, M. R., Williams, L. C., Parsons, V., Weston, M. J.: Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy.Lancet, 2, 219 (1980).
Turney, J. H., Woods, H. F., Weston, M. J.: The use of prostacyclin in extracorporeal circuits.Hemostasis, Prostaglandins and Renal Disease, 353 (1980).
Von Kaulla, K. N., Schultz, R. L.: Methods for evaluation of human fibrinolysis: Studies with two combined techniques.Am. J. Clin. Pathol. 29, 104 (1958).
Wardle, E. N., Piercy, D. A.: Studies of contact activation of blood in hemodialysis.J. Clin. Pathol., 25, 1045 (1972).
Weston, M. J., Woods, H. F., Ash, G., Bunting, S., Moncada, S., Vane, J. R.: Prostacyclin as an alternative to heparin for hemodialysis in dogs. Prostacyclin. Raven Press, New York 1979, p. 349.
Woods, H. F., Ash, G., Weston, M. J., Bunting, S., Moncada, S., Vane, J. R.: Prostacyclin can replace heparin in haemodialysis in dogs.Lancet, 2, 1075 (1978).
Woods, H. F., Weston, M. J., Bunting, S.: Haemodialysis without heparin.Clin. Nephrol., 12, 122 (1979).
Zucker, M. B.: Biological aspects of heparin action. Heparin and platelet function.Fed. Proc., 36, 47 (1977).
Zusman, R., Rubin, R., Cato, A., Cocchetto, D., Crow, J., Tolkoff-Rubin, N.: hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent.N. Engl. J. Med., 304, 934 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kuźnifwski, M., Sułowicz, W. & Lisiewicz, J. Effect of heparin and prostacyclin-heparin infusion on blood coagulation in haemodialysed patients. International Urology and Nephrology 23, 89–96 (1991). https://doi.org/10.1007/BF02549733
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02549733